EMA Close To Finalizing Gene Therapy Products Guidance; No Scope For Further Approximation To International Norms
Executive Summary
The European Medicines Agency says there is no scope to harmonize further its guidance on gene therapy medicinal products with international norms as the main focus of the document is on fulfilling data requirements to support an EU marketing authorization application.
You may also be interested in...
EMA 'Completely Reworks' Parts Of Gene Therapy Products Guideline
The European Medicines Agency has revised several sections of its 2001 guidance on the development and evaluation of gene therapy medicinal products based on stakeholder feedback and to address issues in light of the experience gained with these products.
EMA's Action Plan To Support ATMPs Expected In Jan 2017
The European Medicines Agency's action plan to support the development of advanced therapy medicinal products will prioritize on actions that are feasible, will result in major gains without the need for a lot of effort and will not require legislative changes.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.